Valuation: Orexo AB

Market Cap 46Cr 4.62Cr 4.07Cr 3.84Cr 3.49Cr 6.55Cr 443.69Cr 6.59Cr 18Cr 226.4Cr 17Cr 17Cr 727.54Cr P/E 2026 *
-1.26x
P/E 2027 * -1.81x
Enterprise Value 36Cr 3.57Cr 3.14Cr 2.97Cr 2.69Cr 5.05Cr 342.47Cr 5.08Cr 14Cr 174.76Cr 13Cr 13Cr 561.57Cr EV / Sales 2026 *
18.7x
EV / Sales 2027 * 17x
Free-Float
78.37%
Yield 2026 *
-
Yield 2027 * -
1 day+0.91%
1 week+4.72%
Current month-15.29%
1 month-0.60%
3 months-45.49%
6 months-38.43%
Current year-55.81%
1 week 12.2
Extreme 12.2
13.52
1 month 12.2
Extreme 12.2
16.6
Current year 12.2
Extreme 12.2
36
1 year 12.2
Extreme 12.2
43.4
3 years 9.18
Extreme 9.18
43.4
5 years 8.44
Extreme 8.44
43.4
10 years 8.44
Extreme 8.44
87.9
Manager TitleAgeSince
Chief Executive Officer 54 05/02/2013
Director of Finance/CFO 59 01/09/2022
Chief Tech/Sci/R&D Officer - 01/10/2024
Director TitleAgeSince
Director/Board Member 64 01/01/2002
Director/Board Member 70 11/04/2019
Director/Board Member 62 01/04/2022
Date Insider Type Main position Quantity % Market Cap. Importance
04/09/25 Buy

Chief Executive Officer

6 0.0000%
04/09/25 Free

Chief Executive Officer

1,393 0.0040%
03/09/25 Free 149 0.0004% -
Change 5-day change 1-year change 3-year change Capi.($)
+0.91%+4.72%-56.18%-19.10% 4.64Cr
-0.29%-0.58%+89.14%+42.50% 37TCr
+2.56%+4.41%+29.03%-11.16% 6.69TCr
-0.70%+1.56%+54.44%+189.12% 1.29TCr
-0.93%-0.44%-2.69%-16.04% 754.26Cr
+0.40%-1.93%-24.93%-11.60% 437.87Cr
+0.81%-1.58%-34.87%+3.48% 407.44Cr
-1.08%+1.04%-29.63%-15.59% 302.29Cr
+3.22%+3.20%-7.25%+57.23% 247.97Cr
-0.84%-1.50%-21.36%-28.68% 190.99Cr
Average +0.43%+0.05%-0.43%+19.02% 4.7TCr
Weighted average by Cap. +0.19%+1.56%+74.30%+36.53%

Financials

2026 *2027 *
Net sales 1.9Cr 19.08L 16.78L 15.87L 14.39L 27.03L 18Cr 27.19L 73.38L 9.35Cr 71.64L 70.08L 30Cr 2.7Cr 27.11L 23.85L 22.55L 20.45L 38.41L 26Cr 38.64L 1.04Cr 13Cr 1.02Cr 99.59L 43Cr
Net income -38Cr -3.77Cr -3.31Cr -3.13Cr -2.84Cr -5.34Cr -361.49Cr -5.37Cr -14Cr -184.46Cr -14Cr -14Cr -592.76Cr -
Net Debt -10Cr -1.05Cr -92.74L -87.7L -79.54L -1.49Cr -101.22Cr -1.5Cr -4.06Cr -52Cr -3.96Cr -3.87Cr -165.97Cr -
Logo Orexo AB
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Employees
61
Date Price Change Volume
28/26/28 SEK 13.30 +0.91% 5,584
25/26/25 SEK 13.18 +2.97% 20,859
24/26/24 SEK 12.80 +2.40% 16,148
23/26/23 SEK 12.50 -0.79% 38,672
22/26/22 SEK 12.60 -0.79% 52,276
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Quarterly revenue - Rate of surprise